Four small worlds for one quiet bench.

The short version

KLOW is a research-only co-formulation of four chemically distinct peptides — KPV, BPC-157, GHK-Cu, and TB-500 — dissolved together in a single vial. It is not a drug, not FDA-approved, and the four peptides are not a single molecule. Each one has its own separate research record: KPV damps inflammatory signaling in gut and immune cells, GHK-Cu shifts gene expression toward matrix remodeling and antioxidant defense, BPC-157 promotes angiogenesis in rodent tissue-repair models, and TB-500 carries the actin-binding motif of the native thymosin beta-4 protein. The fifth tile — the combination itself — has never been studied in a controlled setting. Every synergy claim is mechanistic extrapolation. The effects page covers what the research-use community reports, labeled plainly as anecdotal, alongside the cited cautions for athletes, people with cancer histories, and people with copper-handling disorders.

What is in the KLOW blend?

KLOW is a community-coined designation for a four-peptide research vial that compounders most often supply at 80 mg total per vial: GHK-Cu at 50 mg, BPC-157 at 10 mg, TB-500 at 10 mg, and KPV at 10 mg ^[1]. The four peptides are co-dissolved at fixed mass ratios; they do not form a single chemical complex, and there is no FDA-approved or pharmacopeial KLOW product. Each peptide carries its own evidence base and its own mechanism, and the canonical mass ratio is not a clinical decision — it is a vendor convention that has propagated across the research-chemical market.

The four components do not overlap on a single pathway. GHK-Cu is a copper-binding tripeptide that nudges roughly thirty-one percent of the protein-coding genes in cultured fibroblasts at nanomolar concentrations ^[7]. BPC-157 is a fifteen-amino-acid peptide that activates the VEGFR2 / Akt / eNOS angiogenic axis in rodent injury models ^[22]. TB-500 is a seven-amino-acid acetylated fragment of thymosin beta-4 carrying the LKKTET actin-binding motif, though almost all of the published efficacy data uses the full forty-three-amino-acid native protein, not the fragment marketed under that name ^[15]. KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, and it blocks NF-kB nuclear import through a route that is at least partly independent of the melanocortin receptors ^[2][3].

The canonical KLOW vial is therefore an editorial object as much as a chemical one. It bundles four research peptides at four different evidence levels — decades of topical human cosmetic data for GHK-Cu, hundreds of rodent papers for BPC-157, a small clinical program for native thymosin beta-4 plus very limited fragment-level data for TB-500, and a respectable colitis-model literature for KPV. Reading the blend honestly means reading the four literatures separately, which is how this site is arranged.

Four worlds, briefly

Each component owns a color on this site so the four literatures stay distinct as you move between pages. KPV wears sage. BPC-157 wears sky blue. GHK-Cu wears warm tan, after the copper it carries. TB-500 wears coral, as a quiet visual signal that it is the WADA-prohibited component of the four ^[1].

KPV (Lys-Pro-Val) sits at the C-terminus of alpha-MSH. In two independent murine colitis models — dextran-sulfate-sodium-induced and TNBS-induced — oral KPV at one hundred micromolar in drinking water reduced disease activity, inflammatory infiltrates, and pro-inflammatory cytokines, with the di- and tripeptide transporter PepT1 identified as the cellular entry route ^[2]. A 2024 PepT1-targeted nanoparticle co-assembling KPV with the immunosuppressant FK506 extended that signal to chronic DSS colitis and restored tight-junction proteins ZO-1 and Occludin ^[5].

BPC-157 was characterized in the early 2000s as the stable gastric pentadecapeptide. At ten micrograms per kilogram intraperitoneal, it improved tendon-to-bone healing in Achilles-detached rats and offset corticosteroid-induced healing impairment ^[12]. Across separate rat studies it produced functional, biomechanical, and histological recovery of medial collateral ligament transections ^[13] and of gastrocnemius crush injuries ^[14]. A 2025 systematic review of thirty-six studies reaffirmed the rodent musculoskeletal signal and counted only three published human pilot studies ^[20].

GHK-Cu is the oldest peptide of the four. Pickart isolated it from human plasma in 1973, and a 2018 transcriptomic synthesis estimated that nanomolar GHK-Cu altered expression of about four thousand protein-coding genes — roughly thirty-one percent of the coding genome — in cultured fibroblasts, with the strongest signal on extracellular-matrix remodeling, antioxidant defense, and DNA repair ^[7]. Two 2025 papers extended its evidence base: a twenty-milligram-per-kilogram oral gavage protocol alleviated murine DSS colitis with SIRT1 upregulation ^[9], and a GHK-Cu composite hydrogel closed staphylococcus-infected mouse wounds at over ninety-five percent by day twelve ^[10].

TB-500 is the youngest and most contested of the four. The seven-amino-acid acetylated fragment (Ac-LKKTETQ-OH) contains the actin-binding motif of native thymosin beta-4, but the foundational dermal, corneal, and cardiac repair papers use the full forty-three-amino-acid protein ^{[16][17][18][19]}. Fragment-level activity in dermal wound healing has been demonstrated in some models; cardiac and progenitor-mobilization data is essentially all native-protein data. This distinction is the single most consequential nuance in the TB-500 literature.

What about the combination itself?

This is the fifth tile, and it is empty. No controlled in-vivo study has tested the four-peptide KLOW blend against any single component, against any pairwise combination, or against the three-peptide GLOW subset (GHK-Cu + BPC-157 + TB-500). The synergy language found in vendor and community materials is mechanistic extrapolation from single-agent literature, not measurement ^[1].

The mechanistic rationale is reasonable. KPV resolves innate inflammation through NF-kB suppression. BPC-157 supports angiogenesis and connective-tissue repair through VEGFR2 / Akt / eNOS signaling. GHK-Cu drives broad gene-expression shifts toward matrix remodeling and antioxidant defense. TB-500 carries the LKKTET motif that, in native thymosin beta-4, sequesters monomeric G-actin and accelerates cell migration. The four pathways are non-overlapping on paper. Whether they are additive, synergistic, neutral, or antagonistic in a co-formulation is a question the published literature has not answered.

What the rest of this site does, then, is read the four worlds carefully and leave the fifth one transparently unfinished. /research walks each component literature in turn. /dosage assembles the dose ranges used in the source studies without recommending any of them for human use. /faq answers the most-asked combination questions with the answers the literature supports — which are sometimes 'no study has tested this.' /references holds the twenty-two citations behind every numbered claim on the site.

A note on what this site is, and isn't

KLOW Clinic is an independent editorial project. It publishes summaries of the peer-reviewed literature on the four peptides in the KLOW blend and on the blend as a research object. It is not a medical clinic, it does not employ clinicians, and it does not offer medical advice; it has no products to supply and no peptide to manufacture or distribute. The 'clinic' in the domain name is editorial framing — the position the publisher occupies relative to the literature, not a claim about services.

All four components are research peptides. None is approved by the FDA for any human indication. BPC-157, TB-500, and KPV are scheduled for FDA Pharmacy Compounding Advisory Committee evaluation on July 23 and 24 of 2026 ^[1]. TB-500 is explicitly prohibited at all times by the World Anti-Doping Agency under category S2; BPC-157 is listed under S0 ^[1]. Athletes subject to WADA testing should treat the KLOW blend as prohibited because of its BPC-157 and TB-500 components, regardless of the WADA status of GHK-Cu or KPV.

This is a reading bench, not a dispensary: a place to read what the four component literatures actually say and to see, in the empty fifth tile, what no controlled study has yet tested.